ACT’s Chief Scientific Officer Robert

New Post Public Reply Private Reply Replies (0) Message Board
junewong

ACT’s Chief Scientific Officer Robert Lanza, MD, Appointed Editor-in-Chief of BioResearch Open Access Journal

Date : 02/11/2013 @ 11:00AM
Source : Business Wire
Stock : Advanced Cell Tech (ACTC)
Quote : 0.0785  0.0002 (0.26%) @ 4:26PM

ACT’s Chief Scientific Officer Robert Lanza, MD, Appointed Editor-in-Chief of BioResearch Open Access Journal

Advanced Cell Tech (OTCBB:ACTC)
Intraday Stock Chart

Today : Monday 11 February 2013

Click Here for more Advanced Cell Tech Charts.

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader in the regenerative medicine space, announced today that the Company’s chief scientific officer, Robert Lanza, MD, has been appointed editor-in-chief of the scientific journal BioResearch Open Access . The publication’s current editor, Jane Taylor, Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, will continue in her role as Editor.

BioResearch Open Access , in its second year of publication, is a quality peer-reviewed open access journal for the rapid-publication of a broad range of scientific topics including but not limited to molecular and cellular biology, tissue engineering and biomaterials, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. The Journal welcomes basic science and translational research in the form of original research articles, comprehensive review articles, mini-reviews, rapid communications, brief reports, technical reports, hypothesis articles, perspectives, and letters to the editor. All articles in BioResearch Open Access are rapidly reviewed and published online within 4 weeks of acceptance at www.liebertpub.com/biores . Articles are fully open access and posted on the National Institutes of Health’s (NIH) PubMedCentral . BioResearch Open Access is fully NIH-, HHMI-, and Wellcome Trust-compliant.

" BioResearch Open Access is a fully-refereed multidisciplinary journal and provides all the checks and balances that rigorous peer review ensures," said Mary Ann Liebert, president of Mary Ann Liebert, Inc., publishers . "An outstanding editorial team comprised of experienced journal editors guarantees the integrity of the Journal, and we are very pleased to fortify it with the appointment of Dr. Lanza."

According to the European Science Foundation’s Science Policy Briefing (September 2012), “Open access publishing has the potential to revolutionise the way in which biomedical scientists publish and access the latest results in their field.”

Section editors of BioResearch Open Access include the following: James M. Wilson, MD, PhD, University of Pennsylvania; Antonios G. Mikos, PhD, Rice University; Professor Sir Ian Wilmut, OBE FRS FRSE , University of Edinburgh; Peter C. Johnson, MD, Scintellix, LLC, Raleigh, NC; Aubrey D.N.J. de Grey, PhD, SENS Foundation, Cambridge, UK; Alan J. Russell, PhD, Carnegie Mellon University; Thomas Hope, PhD, Northwestern University; Bruce A. Sullenger, PhD, Duke University Medical Center; Graham C. Parker, PhD, Wayne State University School of Medicine; Carol Shoshkes Reiss, PhD, New York University;  Stephen C. Ekker, PhD, Mayo Clinic, Rochester, MN; John B. West, MD, PhD, University of California, San Diego; David L. Woodland, PhD , Chief Scientific Officer, Keystone Symposia on Molecular and Cellular Biology; and Eugene Kolker, PhD, Seattle Children's Hospital.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit www.advancedcell.com .

About the Publisher of BioResearch Open Access

Mary Ann Liebert, Inc. , is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Tissue Engineering, Stem Cells and Development, Human Gene Therapy and HGT Methods, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN) , was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 70 journals, books, and newsmagazines is available at www.liebertpub.com .

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2011. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 92

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 94

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
AI Governance Is Becoming Enterprise Infrastructure

Updated Category News Views 52

Governance Has Finally Reached the Engine Room Enterprise AI is no longer a shiny pilot parked in some innovation lab; it is creeping into business-critical work, and that changes the argument entirely. Frost & Sullivan’s latest analysis makes a sensible point that too many executives still resist: AI governance is becoming a strategic operating capability, not merely a...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 28

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 71

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading
Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 89

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 81

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
Trade Secret Damages Turn on Corporate Intent Evidence

Updated Category News Views 101

Suspicion may rattle a courtroom, but it apparently does not always loosen the jury’s purse strings. That is the useful, slightly sobering takeaway from DOAR’s new national study on damages in trade secret disputes, released November 20, 2026. Jurors, according to the report, draw a meaningful line between an employee carrying experience to a new job and a company...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 43

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Story Cannabis Bets on Neighborly Thanksgiving Outreach

Updated Category News Views 67

A frozen turkey is not a grand strategy deck, thank goodness; it is dinner for a household that might be feeling the squeeze. Story Cannabis plans to hand out 840 of them on Tuesday, Nov. 24, splitting the giveaway between Columbus and Cleveland with former Ohio State and Dallas Cowboys running back Michael Wiley joining employees and volunteers. In a cannabis business...

Continue Reading

Top 5 Most Recently Viewed Articles

DexCom Faces Class Action Lawsuit Over Securities Fraud Claims

Updated Category News Views 104

Overview of the Class Action Against DexCom, Inc. Investors in DexCom, Inc. are currently navigating important developments as a class action lawsuit has been filed. This legal action involves serious allegations of securities fraud against the company. Shareholders who have purchased DexCom securities may be affected, raising important questions about financial integrity...

Continue Reading
Amaroq Minerals Announces AGM Results and Future Directions

Updated Category News Views 209

Amaroq Minerals Ltd. Annual General Meeting Results Amaroq Minerals Ltd. is proud to share the results from its recent Annual General Meeting (AGM), reflecting a robust commitment from shareholders in shaping the future direction of the company. Held in a welcoming atmosphere, the event focused on critical decisions that underscore the corporation's strategic objectives...

Continue Reading
Explore the Theme of Connection and Creation at CIFF 2026

Updated Category News Views 254

Exciting New Developments at CIFF 2026 CIFF, the China International Furniture Fair, is gearing up for its 57th edition in March 2026. With a fresh theme, "CONNECT • CREATE", the event reflects the dynamic landscape of the furniture industry. The fair will facilitate exceptional connections within the furniture supply chain, including production, distribution, and...

Continue Reading
SpaceX's Starship to Showcase Advanced Starlink Technologies

Updated Category News Views 545

SpaceX's Latest Milestone in Satellite Technology Elon Musk's company, SpaceX, is gearing up for an exciting upcoming test flight of its Starship launch vehicle. The mission's highlight is the planned deployment of 10 model Starlink satellites, marking a significant step in demonstrating SpaceX's prowess in the satellite launch industry. The Innovative Starlink Satellites...

Continue Reading
DATAMYTE Introduces AI Efficiency in Mobile Inspections for APQP

Updated Category News Views 354

Transforming Quality Inspections with AI at DATAMYTE DATAMYTE, a leader in manufacturing technology, is truly reshaping the way inspections are conducted in the industry. By utilizing its innovative DIGITAL CLIPBOARD mobile platform alongside the powerful DATAMYTE GPT Artificial Intelligence System, the company is redefining the manual processes traditionally associated...

Continue Reading